1. Home
  2. FLX vs QNTM Comparison

FLX vs QNTM Comparison

Compare FLX & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLX
  • QNTM
  • Stock Information
  • Founded
  • FLX 2013
  • QNTM 1998
  • Country
  • FLX China
  • QNTM Canada
  • Employees
  • FLX N/A
  • QNTM N/A
  • Industry
  • FLX
  • QNTM
  • Sector
  • FLX
  • QNTM
  • Exchange
  • FLX NYSE
  • QNTM NYSE
  • Market Cap
  • FLX N/A
  • QNTM 69.3M
  • IPO Year
  • FLX 2024
  • QNTM N/A
  • Fundamental
  • Price
  • FLX $3.32
  • QNTM $18.56
  • Analyst Decision
  • FLX
  • QNTM
  • Analyst Count
  • FLX 0
  • QNTM 0
  • Target Price
  • FLX N/A
  • QNTM N/A
  • AVG Volume (30 Days)
  • FLX 86.7K
  • QNTM 408.2K
  • Earning Date
  • FLX 08-27-2025
  • QNTM 08-13-2025
  • Dividend Yield
  • FLX N/A
  • QNTM N/A
  • EPS Growth
  • FLX N/A
  • QNTM N/A
  • EPS
  • FLX N/A
  • QNTM N/A
  • Revenue
  • FLX $595,490,250.00
  • QNTM N/A
  • Revenue This Year
  • FLX N/A
  • QNTM N/A
  • Revenue Next Year
  • FLX N/A
  • QNTM N/A
  • P/E Ratio
  • FLX N/A
  • QNTM N/A
  • Revenue Growth
  • FLX N/A
  • QNTM N/A
  • 52 Week Low
  • FLX $2.01
  • QNTM $2.70
  • 52 Week High
  • FLX $21.95
  • QNTM $38.25
  • Technical
  • Relative Strength Index (RSI)
  • FLX N/A
  • QNTM 50.64
  • Support Level
  • FLX N/A
  • QNTM $15.88
  • Resistance Level
  • FLX N/A
  • QNTM $24.32
  • Average True Range (ATR)
  • FLX 0.00
  • QNTM 3.58
  • MACD
  • FLX 0.00
  • QNTM -1.07
  • Stochastic Oscillator
  • FLX 0.00
  • QNTM 13.59

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Share on Social Networks: